Fleury S.A. (BVMF:FLRY3)
Brazil
· Delayed Price · Currency is BRL | Market Cap | 8.71B |
| Revenue (ttm) | 8.29B |
| Net Income (ttm) | 612.83M |
| Shares Out | 545.02M |
| EPS (ttm) | 1.12 |
| PE Ratio | 14.22 |
| Forward PE | 12.70 |
| Dividend | 1.21 (7.56%) |
| Ex-Dividend Date | Dec 3, 2025 |
| Volume | 3,282,200 |
| Average Volume | 2,614,215 |
| Open | 15.88 |
| Previous Close | 15.99 |
| Day's Range | 15.72 - 16.03 |
| 52-Week Range | 12.16 - 18.10 |
| Beta | 0.35 |
| RSI | 42.79 |
| Earnings Date | May 7, 2026 |
About Fleury
Fleury S.A., together with its subsidiaries, provides diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides health management services, such as telemedicine; orthopedic medicine services; laboratory support; toxicological exam; preventive, integrated solutions, and clinical research in oncology; integrated solutions, research, development of processes and services in genomics; and laboratory analysis services. In add... [Read more]
Financial Performance
In 2025, Fleury's revenue was 8.29 billion, an increase of 7.89% compared to the previous year's 7.68 billion. Earnings were 612.83 million, a decrease of -0.54%.
Financial StatementsNews
Fleury Earnings Call Transcript: Q4 2025
Delivered strong revenue and EBITDA growth in 2025, driven by B2C, B2B, and New Links expansion, disciplined cost management, and strategic acquisitions. Maintained stable margins, robust cash generation, and increased ROIC, with continued focus on digital transformation and operational efficiency.
Fleury SA (BSP:FLRY3) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...
Fleury SA (BSP:FLRY3) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic Expansion
Q3 2025 Fleury SA Earnings Call (English, Portuguese) Transcript
Q3 2025 Fleury SA Earnings Call (English, Portuguese) Transcript
Fleury Earnings Call Transcript: Q3 2025
Q3 2025 saw 11.5% revenue growth, strong B2C and mobile care expansion, and stable margins. Strategic acquisitions in São Paulo and Campinas enhanced market presence, while robust cash flow and disciplined capital allocation supported high dividends and future growth.
Fleury Earnings Call Transcript: Q2 2025
Q2 2025 saw modest revenue growth and stable EBITDA, but net income declined due to calendar effects and contract terminations. Investments in digitalization and recent acquisitions support future growth, with a strong cash position and disciplined capital allocation.
Fleury SA (BSP:FLRY3) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Fleury SA (BSP:FLRY3) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion
Q1 2025 Fleury SA Earnings Call (English, Portuguese) Transcript
Q1 2025 Fleury SA Earnings Call (English, Portuguese) Transcript
Fleury Earnings Call Transcript: Q1 2025
Q1 2025 saw 6.5% revenue growth, strong B2C and regional brand performance, and robust digital adoption, with EBITDA and net profit up 5.9% and 6.7% respectively. ROIC improved to 16.9%, leverage remained low, and high payout was maintained.
Fleury Earnings Call Transcript: Q4 2024
Strong revenue and net income growth in 2024, driven by successful integration, digital innovation, and strategic acquisitions. Margins expanded, cash generation was robust, and the company remains well-positioned for continued market share gains and operational efficiency.
Fleury SA (BSP:FLRY3) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Market ...
Fleury SA (BSP:FLRY3) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Market Challenges
Q3 2024 Fleury SA Earnings Call (English, Portuguese) Transcript
Q3 2024 Fleury SA Earnings Call (English, Portuguese) Transcript
Fleury Earnings Call Transcript: Q3 2024
Q3 2024 saw 6.1% revenue growth to BRL 2.1B, with EBITDA up 6.2% and net profit up 9.5%. Integration with Pardini and expansion in B2B, mobile, and new health platforms drove results, while cost discipline and digital initiatives supported margins.
Fleury Earnings Call Transcript: Q2 2024
Q2 2024 saw 19.7% revenue growth and 47.5% higher net income, driven by the Pardini integration, B2B expansion, and cost discipline. Synergy capture is on track, leverage remains low, and the group continues to diversify revenue and invest in digital initiatives.